Quick Answer
Translational Development Acquisition Corp. reported Stockholders Equity of -$6.54 million for fiscal year 2025.
Translational Development Acquisition Corp. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | -$6.54M | -16.9% |
| 2024 | -$5.60M | -1002.6% |
| 2023 | -$507.7K | -2196.3% |
| 2022 | -$22.1K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$6.38M | -1018.0% | -3.5% |
| June 30, 2025 | -$6.17M | -1110.6% | -3.7% |
| March 31, 2025 | -$5.94M | -1071.1% | -6.2% |
| December 31, 2024 | -$5.60M | -1002.6% | -881.0% |
| September 30, 2024 | -$570.6K | — | -12.0% |
| June 30, 2024 | -$509.3K | — | -0.3% |
| March 31, 2024 | -$507.7K | — | +0.0% |
| December 31, 2023 | -$507.7K | — | — |
- Translational Development Acquisition Corp. showed a decrease of -16.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2022–2025 period, Translational Development Acquisition Corp.’s stockholders equity has declined by 29491.6% (from -$22.1 thousand to -$6.54 million).
- The most recent figure is from Translational Development Acquisition Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: